Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


 

Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail.

Recent News:

 

12/16/2014 Hemispherx’s Ampligen® Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors
…Positive Effects Reported in a Melanoma Model


12/9/2014 Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen® Enlarged by Howard University Research
… Independent Demonstration of Anti-Ebola Function of Hemispherx’s Biotherapeutic


11/17/2014 Ampligen® Blocks Critical Ebola Viral Disease (EVD) Protein Which Is Linked To High Mortality in Man
… European University Report Establishes that VP35 Binding by Ampligen® May Restore Ability to Activate Effective Immune Response and Thereby Survive Infection


11/14/2014 Hemispherx Biopharma Reports on Annual Stockholder Meeting

11/10/2014 Hemispherx Biopharma Announces Financial Results for the Nine Months Ended September 30, 2014
. . .U.S. Governmental Collaboration Indicates that Ampligen® and Alferon® Both Exhibit In Vitro Antiviral Activity Against the Ebola Virus


More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

McGladrey & Pullen, LLP

 

Investor Relations:

Charles Jones
CJones & Associates Public Relations
888-557-6480
cjones@cjonespr.com